Today’s Daily Dive welcomes back Dr. George Adams, Executive Chairman of VentriPoint Diagnostics (TSXV: VPT). He expounds on salient topics including the effect of COVID-19 on the heart’s health, the role of an improved cardiovascular healthcare system during the pandemic, and the involvement of the company’s echocardiogram innovation within that space.
The biotech firm’s chief officer also touches on the company’s collaborative agreement with GE Healthcare and the partnership with National Research Council of Canada’s Industrial Research Assistance Program.
Ventripoint Diagnostics has become an industry leader in the application of Artificial Intelligence to echocardiography. The company’s VMS products provide accurate volumetric cardiac measurements equivalent to an MRI.
In layman terms, the company is able to accurately create a three dimensional model of a heart based on a two dimensional image produced via an echocardiogram. With the technology settled in the latest version of the product, the company has now begun selling the product to some of the world’s leading hospitals.
FULL DISCLOSURE: Ventripoint Diagnostics is a client of Canacom Group, the parent company of The Deep Dive. The company has been compensated to cover Ventripoint Diagnostics on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
Bank Of America Lowers Gold Price Target To $2000? – The Daily Dive feat John-Mark Staude
Returning to the Daily Dive today is that of John-Mark Staude of Riverside Resources (TSXV:...